Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 258Breast Neoplasms 218Lung Neoplasms 207Glioblastoma 202Head and Neck Neoplasms 193Prostatic Neoplasms 179Squamous Cell Carcinoma of Head and Neck 171Lymphoma 152Rectal Neoplasms 139Esophageal Neoplasms 125Central Nervous System Neoplasms 122Leukemia 111Brain Neoplasms 107Pancreatic Neoplasms 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 87Esophageal Squamous Cell Carcinoma 84Sarcoma 82Uterine Cervical Neoplasms 81Neoplasms 81Lymphoma, Follicular 81Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Non-Hodgkin 75Hodgkin Disease 74Glioma 68Burkitt Lymphoma 67Colorectal Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 63Astrocytoma 63Neoplasm Metastasis 60

Interventions

tazemetostat 1osimertinib 1itacitinib 1Radiotherapy 1Lovastatin 1INCB039110 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inhibition, Psychological × Radiotherapy × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡